Streetbeat News

ENTX

Entera Bio Ltd.

https://www.enterabio.com

Industry

Biotechnology

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Open

1.80

Mkt cap

64M

Volume

17K

High

1.83

P/E Ratio

-6.73

52-wk high

3.35

Low

1.75

Div yield

N/A

52-wk low

0.52

Entera Bio Ltd. (NASDAQ:ENTX) presented Phase 1 clinical data for its oral PTH(1-34) peptide candidate, EB612, for hypoparathyroidism at the ENDO 2024 Annual Meeting. The program aims to provide the first oral PTH daily tablet hormone replacement therapy, contrasting with current injectable treatments by Ascendis Pharma and Amolyt Pharma.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:14 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Entera Bio (NASDAQ:ENTX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:31 am

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Entera Bio (NASDAQ:ENTX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:58 am

Entera Bio (NASDAQ:ENTX) reported Q1 earnings with losses of $(0.05) per share, surpassing the analyst consensus estimate of $(0.06) by 16.67%. This represents a 37.5% improvement over the previous year's losses of $(0.08) per share.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:39 pm

Entera Bio (NASDAQ:ENTX) reported Q1 earnings of $0.05 per share, surpassing the analyst consensus estimate of $(0.06) by 183.33%. This represents a significant improvement from the $(0.08) per share loss reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:18 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Entera Bio (NASDAQ:ENTX) with a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:54 pm

Entera Bio Ltd. (NASDAQ:ENTX) announced the FDA's plan to rule within 10 months on using bone mineral density (BMD) as a surrogate endpoint for osteoporosis drug trials. This decision could benefit Entera's EB613, a first-in-class oral treatment for osteoporosis, currently in Phase 3, designed to meet the BMD thresholds proposed by the SABRE project. The approval of BMD as a surrogate endpoint could streamline the approval process for new osteoporosis treatments, addressing a significant treatment gap in a disease affecting over 200 million women globally.

Portfolio Pulse from Happy Mohamed

March 26, 2024 | 12:33 pm

Entera Bio announced successful pharmacokinetic data for its oral GLP-2 peptide tablet treatment for patients with Short Bowel Syndrome, indicating significant systemic exposure. This development marks a positive step forward in the treatment's clinical progress.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:03 pm

Entera Bio reported a narrower FY23 EPS loss of $(0.31) compared to $(0.41) YoY, with a decrease in operating expenses and net loss. The company has $11.0M in cash, expected to last through Q2 2025. R&D expenses fell to $4.5M from $5.8M, while G&A expenses dropped to $4.4M from $7.3M, contributing to a reduced net loss of $8.9M from $13.1M.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:17 pm

Entera Bio Ltd. (NASDAQ:ENTX), a leader in orally delivered peptides, has regained compliance with NASDAQ's minimum bid price requirement for continued listing on The NASDAQ Capital Market. This was achieved by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days as of March 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.